La vendita allo scoperto per TELA Bio dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di TELA Bio. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

TELA Bio (NASDAQ:TELA) Azioni, Report sulle vendite allo scoperto

TELA Bio

TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.

Albany International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIN#NYSE">AIN</a>) affirms FY2025 Adj EPS guidance from $3.00-$3.40 to $3.00-$3.40 vs $3.21 analyst estimate. Affirms FY2025 sales outlook from $1.17 billion-$1.26 billion to $1.17 billion-$1.26 billion vs $1.22 billion estimate.

News

Guidance

Albany International Affirms FY2025 Adj EPS Guidance of $3.00-$3.40 vs $3.21 Est; Affirms FY2025 Sales Guidance of $1.17B-$1.26B vs $1.22B Est

Twin Hospitality Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWNP#NASDAQ">TWNP</a>) reported $87.846 million in sales this quarter. This is a 4.09 percent decrease over sales of $91.594 million the same period last year.

Earnings

TWNP

Twin Hospitality Group Q2 Sales $87.846M Down From $91.594M YoY

Alkami Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKT#NASDAQ">ALKT</a>) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $0.07 by 20 percent. This is a 80 percent increase over earnings of $0.05 per share from the same period last year. The company reported quarterly sales of $112.10 million which beat the analyst consensus estimate of $110.01 million by 1.90 percent. This is a 36.44 percent increase over sales of $82.16 million the same period last year.

Earnings Beats

ALKT

UPDATE: Alkami Technology Q2 Adj. EPS $0.09 Beats $0.07 Estimate, Sales $112.10M Beat $110.01M Estimate

Tronox Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TROX#NYSE">TROX</a>) narrows FY2025 sales outlook from $3.00 billion-$3.40 billion to $3.00 billion-$3.10 billion vs $3.07 billion estimate.

TROX

Tronox Holdings Narrows FY2025 Sales Guidance from $3.00B-$3.40B to $3.00B-$3.10B vs $3.07B Est

Dividends

STERIS Raises Dividend From $0.57 To $0.63/Share

Valaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAL#NYSE">VAL</a>) reported quarterly earnings of $1.61 per share which beat the analyst consensus estimate of $1.29 by 24.81 percent. This is a 20.69 percent decrease over earnings of $2.03 per share from the same period last year. The company reported quarterly sales of $615.20 million which beat the analyst consensus estimate of $583.25 million by 5.48 percent. This is a 0.84 percent increase over sales of $610.10 million the same period last year.

Valaris Q2 EPS $1.61 Beats $1.29 Estimate, Sales $615.20M Beat $583.25M Estimate

RICHMOND, Va., July 30, 2025 /PRNewswire/ -- Markel Insurance, the insurance operations within Markel Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MKL#NYSE">MKL</a>), has entered into an agreement to sell the renewal rights for its Global Reinsurance business to Nationwide. The sale is part of Markel's broader strategy to simplify operations and grow the business by empowering local expert teams to serve the distinct needs of their core specialty insurance markets.
&nbsp;
"We are grateful for the work that our Global Reinsurance team has done for our valued customers, but our scale has held us back from being a leader in the reinsurance market," said Simon Wilson, Chief Executive Officer of Markel Insurance. "With this change, we will sharpen our focus on doing more of what we do best by growing our core specialty insurance business."
Nationwide intends to delegate the underwriting and management of all renewal policies included in this transaction to Ryan Re Underwriting Managers ("Ryan Re"), a managing general underwriter of Ryan Specialty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RYAN#NYSE">RYAN</a>), through the expansion of their existing strategic alliance. Markel will not sell any insurance company entities as part of the transaction, and Markel's Global Reinsurance division will enter runoff, with premiums continuing to earn out over the next two to three years. The transaction is subject to customary closing conditions and is expected to close in August 2025.
"Nationwide and Ryan Re have the scale, market presence, and expertise necessary to leverage these renewal rights to build an even stronger foundation for long-term success," said Wilson. "We are confident that they will deliver for our reinsurance customers and trading partners."
Transaction terms have not been publicly disclosed.

General

RYAN

Markel Insurance Sells The Renewal Rights For Its Global Reinsurance Business To Nationwide; Terms Not Disclosed

Albany Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIN#NYSE">AIN</a>) reported quarterly earnings of $0.57 per share which missed the analyst consensus estimate of $0.74 by 22.97 percent. This is a 35.96 percent decrease over earnings of $0.89 per share from the same period last year. The company reported quarterly sales of $311.00 million which beat the analyst consensus estimate of $306.06 million by 1.61 percent. This is a 6.32 percent decrease over sales of $331.99 million the same period last year.

Earnings Misses

Albany Intl Q2 Adj. EPS $0.57 Misses $0.74 Estimate, Sales $311.00M Beat $306.06M Estimate

National Fuel Gas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NFG#NYSE">NFG</a>) is looking for FY2026 Adj EPS of $8.00-$8.50 vs $8.51 analyst estimate..

National Fuel Gas Sees FY2026 Adj EPS $8.00-$8.50 vs $8.51 Est

VSE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEC#NASDAQ">VSEC</a>) affirms FY2025 sales outlook from $1.46 billion-$1.51 billion to $1.46 billion-$1.51 billion vs $1.09 billion estimate.

VSEC

VSE Affirms FY2025 Sales Guidance of $1.46B-$1.51B vs $1.09B Est

Albany International Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIN#NYSE">AIN</a>) announced today that its Board of Directors has appointed Willard Station as Executive Vice President – Chief Financial Officer, and elected him an officer of the Company effective September 1, 2025. Mr. Station has also been appointed Principal Financial Officer, succeeding Jairaj (JC) Chetnani, the Company's Vice President – Investor Relations and Treasurer, who has served as interim Chief Financial Officer since May 23, 2025.

Management

Albany International Appoints Willard Station As CFO, Succeeding Interim Finance Chief Jairaj Chetnani, Effective September 1, 2025

Orange County Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBT#NASDAQ">OBT</a>) reported quarterly earnings of $0.87 per share which beat the analyst consensus estimate of $0.53 by 64.15 percent. This is a 19.18 percent increase over earnings of $0.73 per share from the same period last year. The company reported quarterly sales of $32.46 million which beat the analyst consensus estimate of $29.15 million by 11.34 percent. This is a 16.22 percent increase over sales of $27.93 million the same period last year.

Orange County Bancorp Q2 EPS $0.87 Beats $0.53 Estimate, Sales $32.46M Beat $29.15M Estimate

PLPC

Preformed Line Products Q2 EPS $2.56 Up From $1.89 YoY, Sales $169.601M Up From $138.720M YoY

Lam Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) is looking for Q1 Adj EPS of $1.10-$1.30 vs $0.98 analyst estimate. sees sales of $4.900 billion-$5.500 billion vs $4.607 billion analyst estimate.

LRCX

Lam Research Sees Q1 Adj EPS $1.10-$1.30 vs $0.98 Est; Sees Sales $4.900B-$5.500B vs $4.607B Est

Omega Flex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFLX#NASDAQ">OFLX</a>) reported quarterly earnings of $0.41 per share. This is a 8.89 percent decrease over earnings of $0.45 per share from the same period last year. The company reported $48.85 million in sales this quarter. This is a 98.44 percent increase over sales of $24.62 million the same period last year.

OFLX

Omega Flex Q2 EPS $0.41 Down From $0.45 YoY, Sales $48.85M Up From $24.62M YoY

American Water Works Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AWK#NYSE">AWK</a>) raises FY2025 GAAP EPS guidance from $5.65-$5.75 to $5.70-$5.75 vs $5.72 analyst estimate..

American Water Works Co Raises FY2025 GAAP EPS Guidance from $5.65-$5.75 to $5.70-$5.75 vs $5.72 Est

Lam Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) is looking for Q1 GAAP EPS of $1.10-$1.30 vs $0.97 analyst estimate..

Lam Research Sees Q1 GAAP EPS $1.10-$1.30 vs $0.97 Est

National Fuel Gas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NFG#NYSE">NFG</a>) narrows FY2025 Adj EPS guidance from $6.75-$7.05 to $6.80-$6.95 vs $6.94 analyst estimate..

National Fuel Gas Narrows FY2025 Adj EPS Guidance from $6.75-$7.05 to $6.80-$6.95 vs $6.94 Est

Guardant Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>) raises FY2025 sales outlook from $880.00 million-$890.00 million to $915.00 million-$925.00 million vs $885.17 million estimate.

Guardant Health Raises FY2025 Sales Guidance from $880.00M-$890.00M to $915.00M-$925.00M vs $885.17M Est

CBIZ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBZ#NYSE">CBZ</a>) affirms FY2025 GAAP EPS guidance from $1.97-$2.02 to $1.97-$2.02 vs $1.96 analyst estimate..

Comments

TELA Bio

Vendite allo scoperto

TELA Bio (NASDAQ:TELA) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO